EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome

Frank Haessler, Franziska Gaese, Michael Colla, Michael Huss, Christoph Kretschmar, Marc Brinkman, Heike Schieb, Helmut Peters, Samuel Elstner, David Pittrow, Frank Haessler, Franziska Gaese, Michael Colla, Michael Huss, Christoph Kretschmar, Marc Brinkman, Heike Schieb, Helmut Peters, Samuel Elstner, David Pittrow

Abstract

Background: Fragile X syndrome (FXS), caused by a mutation of the FMR1 gene on the X chromosome, is the most common inherited form of intellectual disability and autism spectrum disorders. Comprehensive data are lacking, however, on the characteristics and management patients with FXS in Germany.

Methods/design: EXPLAIN is a prospective, observational, longitudinal registry with a non-probability sampling approach. It collects data on patient characteristics, therapeutic interventions, psychosocial parameters (including those of family members and caregivers), quality of life of caregiver and patient, caregiver burden, and health economic parameters, such as hospitalisation time. It is designed to include data from 300 patients in ambulatory care from about 50 centres that employ psychiatrists, paediatricians, neurologists, and other relevant specialists, in Germany. The study was initiated in March, 2013. Patients will be followed for at least two years.

Discussion: The registry is expected to provide much-needed data on the characteristics and management of patients with FXS in Germany. It will also allow comparisons with other countries, and will enable gap analyses based on current guidelines for management of these patients.

Trial registration: The ClinicalTrials.gov identifier is NCT01711606.

References

    1. Wang T, Bray SM, Warren ST. New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev. 2012;13(3):256–263. doi: 10.1016/j.gde.2012.02.002.
    1. de Vries BB, Mohkamsing S, van den Ouweland AM, Mol E, Gelsema K, van Rijn M, Tibben A, Halley DJ, Duivenvoorden HJ, Oostra BA. et al.Screening for the fragile X syndrome among the mentally retarded: a clinical study. The collaborative fragile X study group. J Med Genet. 1999;13(6):467–470.
    1. Carter MT, Scherer SW. Autism spectrum disorder in the genetics clinic: a review. Clin Genet. 2013;13(5):399–407. doi: 10.1111/cge.12101.
    1. Lewis P, Abbeduto L, Murphy M, Richmond E, Giles N, Bruno L, Schroeder S. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res. 2006;13(Pt 7):532–545.
    1. Barnes E, Roberts J, Long SH, Martin GE, Berni MC, Mandulak KC, Sideris J. Phonological accuracy and intelligibility in connected speech of boys with fragile X syndrome or Down syndrome. J Speech Lang Hear Res. 2009;13(4):1048–1061. doi: 10.1044/1092-4388(2009/08-0001).
    1. Deshpande PS, Coffey DB. Fragile X syndrome and attention-deficit/hyperactivity disorder symptoms. J Child Adolesc Psychopharmacol. 2011;13(6):639–642. doi: 10.1089/cap.2011.2164.
    1. Baker JK, Seltzer MM, Greenberg JS. Behaviour problems, maternal internalising symptoms and family relations in families of adolescents and adults with fragile X syndrome. J Intellect Disabil Res. 2012;13(10):984–995. doi: 10.1111/j.1365-2788.2012.01580.x.
    1. McCary LM, Roberts JE. Early identification of autism in fragile X syndrome: a review. J Intellect Disabil Res. 2013;13(9):803–814. doi: 10.1111/j.1365-2788.2012.01609.x.
    1. Gabis LV, Baruch YK, Jokel A, Raz R. Psychiatric and autistic comorbidity in fragile X syndrome across ages. J Child Neurol. 2011;13(8):940–948. doi: 10.1177/0883073810395937.
    1. Sabaratnam M, Murthy NV, Wijeratne A, Buckingham A, Payne S. Autistic-like behaviour profile and psychiatric morbidity in Fragile X Syndrome: a prospective ten-year follow-up study. Eur Child Adolesc Psychiatry. 2003;13(4):172–177. doi: 10.1007/s00787-003-0333-3.
    1. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB. Seizures in fragile X syndrome: characteristics and comorbid diagnoses. Am J Intellect Dev Disabil. 2010;13(6):461–472. doi: 10.1352/1944-7558-115.6.461.
    1. Sofocleous C, Kolialexi A, Mavrou A. Molecular diagnosis of Fragile X syndrome. Expert Rev Mol Diagn. 2009;13(1):23–30. doi: 10.1586/14737159.9.1.23.
    1. Rueda JR, Ballesteros J, Tejada MI. Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol. 2009;13:53. doi: 10.1186/1471-2377-9-53.
    1. Bailey DB Jr, Raspa M, Bishop E, Olmsted M, Mallya UG, Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Pediatr. 2012;13(1):62–69. doi: 10.1097/DBP.0b013e318236c0e1.
    1. Martin GE, Ausderau KK, Raspa M, Bishop E, Mallya U, Bailey DB Jr. Therapy service use among individuals with fragile X syndrome: findings from a US parent survey. J Intellect Disabil Res. 2013;13(9):837–849. doi: 10.1111/j.1365-2788.2012.01608.x.
    1. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012;13:297–335. doi: 10.1007/978-3-642-21649-7_17.
    1. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, Song C, Buijsen RA, Pop AS, Gomezmancilla B. et al.AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis. 2011;13(3):311–317. doi: 10.1016/j.nbd.2011.01.022.
    1. Giangreco CA, Steele MW, Aston CE, Cummins JH, Wenger SL. A simplified six-item checklist for screening for fragile X syndrome in the pediatric population. J Pediatr. 1996;13(4):611–614. doi: 10.1016/S0022-3476(96)70130-0.
    1. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale–preliminary report. Psychopharmacol Bull. 1973;13(1):13–28.
    1. Kubinger K. The intelligence test-battery AID 2 as a prototypical globalized test. Testing International. 2008;13:13–14.
    1. Petermann F, Petermann U. HAWIK-IV. 3. Bern, Switzerland: Huber Verlag; 2010.
    1. Melchers P, Preuß U. Kaufman Assessment Battery for Children. 8. Frankfurt/Main, Germany: Pearson Assessment; 2009.
    1. Harris SH. An evaluation of the Snijders-Oomen nonverbal intelligence scale for young children. J Pediatr Psychol. 1982;13(3):239–251. doi: 10.1093/jpepsy/7.3.239.
    1. Newton JT, Sturmey P. The aberrant behaviour checklist: a British replication and extension of its psychometric properties. J Ment Defic Res. 1988;13(Pt 2):87–92.
    1. Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Greiner W, Gusi N, Herdman M. et al.Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;13(6):875–886. doi: 10.1007/s11136-010-9648-y.
    1. Loyd BH, Abidin RR. Revision of the parenting stress index. J Pediatr Psychol. 1985;13(2):169–177. doi: 10.1093/jpepsy/10.2.169.
    1. Honigfeld G. NOSIE–30: history and current status of its use in pharmacopsychiatric research. Mod Probl Pharmacopsychiatry. 1974;13:238–263.
    1. Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: a treatment-sensitive ward behavior scale. Psychol Rep. 1966;13(1):180–182. doi: 10.2466/pr0.1966.19.1.180.
    1. Linden M, Baron S, Muschalla B. Mini-ICF-Rating für Aktivitäts- und Partizipationsstörungen bei psychischen Erkrankungen. Gottingen, Germany: Hogreve Verlag; 2013.
    1. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) MedDRA (Medical Dictionary for Regulatory Activities). Internet. : ; . Accessed on 18 December 2013.
    1. Federal Institute for Drugs and Medical Products (BfArM) Recommendations of the Federal Institute for Drugs and Medical Products and the Paul Ehrlich Institute on the planning, conduct and analysis of post marketing studies dated 7 July 2010. Internet. : ; . Accessed on 18 December 2013.
    1. German Association of Research-based Pharmaceutical Companies (Verband der forschenden Arzneimittelhersteller VFA) Rules for publication of post-marketing surveillance studies. : ; Internet: . Accessed on 18 December 2013.
    1. Hartley SL, Seltzer MM, Raspa M, Olmstead M, Bishop E, Bailey DB. Exploring the adult life of men and women with fragile X syndrome: results from a national survey. Am J Intellect Dev Disabil. 2011;13(1):16–35. doi: 10.1352/1944-7558-116.1.16.
    1. Bailey DB, Raspa M, Olmsted MG. Using a parent survey to advance knowledge about the nature and consequences of fragile X syndrome. Am J Intellect Dev Disabil. 2010;13(6):447–460. doi: 10.1352/1944-7558-115.6.447.
    1. Bailey DB, Raspa M, Holiday D, Bishop E, Olmsted M. Functional skills of individuals with fragile x syndrome: a lifespan cross-sectional analysis. Am J Intellect Dev Disabil. 2009;13(4):289–303. doi: 10.1352/1944-7558-114.4.289-303.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner